High expression of glycolytic regulation genes encoding glucose transporters (e.g., GLUT-1) and enzymes (e.g., PKM2) is predicted to be associated with poor survival in patients with melanoma (Falkenius et al., 2013; Koch et al., 2015; Nájera et al., 2019). Here, SLC2A1 is linked to melanoma.